Assessment of Parkinson's disease with imaging

Parkinsonism and Related Disorders

Volumn 13, Issue SUPPL. 3, 2007, Pages

  Brooks, David J ^a  

^a MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

Author keywords

Magnetic resonance imaging; Multiple system atrophy; Positron emission tomography; Prkinson's disease; SPECT; Transcranial sonography

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; IODINE 123; LEVODOPA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE C 11; PLACEBO; PRAMIPEXOLE; RADIOPHARMACEUTICAL AGENT; RILUZOLE; ROPINIROLE; UNCLASSIFIED DRUG;

ARTICLE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; DEMENTIA; DEPRESSION; DISEASE COURSE; DOPPLER ECHOGRAPHY; DRUG UPTAKE; HUMAN; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NORADRENERGIC SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SEROTONINERGIC SYSTEM; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREMOR;

CATECHOLAMINES; DEMENTIA; DEPRESSION; DIAGNOSTIC IMAGING; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; TREMOR;

EID: 38949150391     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(08)70015-4     Document Type: Article

References (55)

1. Berg D., Siefker C., and Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 248 (2001) 684-689
2. Berg D., Roggendorf W., Schroder U., Klein R., Tatschner T., Benz P., et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59 (2002) 999-1005
3. Berg D., Merz B., Reiners K., Naumann M., and Becker G. Five-year follow- up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 20 (2005) 383-385
4. Hutchinson M., and Raff U. Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. Am J Neuroradiol 21 (2000) 697-701
5. Hu M., White S., Herlihy A., Chaudhuri K., Hajnal J., and Brooks D. A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. Neurology 56 (2001) 1195-1200
6. Minati L., Grisoli M., Carella F., De Simone T., Bruzzone M., and Savoiardo M. Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. Am J Neuroradiol 28 (2007) 309-313
7. Michaeli S., Oz G., Sorce D., Garwood M., Ugurbil K., Majestic S., et al. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disord 22 (2007) 334-340
8. Seppi K., Schocke M., Esterhammer R., Kremser C., Brenneis C., Mueller J., et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 60 (2003) 922-927
9. Nicoletti G., Lodi R., Condino F., Tonon C., Fera F., Malucelli E., et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 129 (2006) 2679-2687
10. Brooks D., Frey K., Marek K., Oakes D., Paty D., Prentice R., et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 184 (2003) S68-S79
11. 18F-dopa PET study. Ann Neurol 53 (2003) 206-213
12. 18F-dopa PET study. Neurology 42 (1992) 1554-1560
13. 123I]-FP-CIT Study Group. Mov Disord 15 (2000) 503-510
14. 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 19 (2004) 1175-1182
15. 123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 61 (2004) 1224-1229
16. 123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 28 (2001) 266-272
17. Scherfler C., Schwarz J., Antonini A., Grosset D., Valldeoriola F., Marek K., et al. Role of DAT-SPECT in the diagnostic work up of Parkinsonism. Mov Disord 22 (2007) 1229-1238
18. Vingerhoets F., Schulzer M., Calne D., and Snow B. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?. Ann Neurol 41 (1997) 58-64
19. Benamer H., Patterson J., Wyper D., Hadley D., Macphee G., and Grosset D. Correlation of Parkinson's disease severity and duration with I-123-FP-CIT SPECT striatal uptake. Mov Disord 15 (2000) 692-698
20. Lamarre Y. Animal models of tremor. In: Findley L., and Capildeo R. (Eds). Movement disorders: tremor (1984), MacMillan Press, London 183-194
21. Doder M., Rabiner E., Turjanski N., Lees A., and Brooks D. Tremor in Parkinson's disease and serotonergic dysfunction: An (11)C-WAY 100635 PET study. Neurology 60 (2003) 601-605
22. 123I-beta- CIT SPECT. J Nucl Med 44 (2003) 870-876
23. Remy P., Doder M., Lees A., Turjanski N., and Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128 (2005) 1314-1322
24. Kuhl D., Minoshima S., Fessler J., Frey K., Foster N., Ficaro E., et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 40 (1996) 399-410
25. Bohnen N., Kaufer D., Ivanco L., Lopresti B., Koeppe R., Davis J., et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60 (2003) 1745-1748
26. Bohnen N., Kaufer D., Hendrickson R., Ivanco L., Lopresti B., Davis J., et al. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci Lett 380 (2005) 127-132
27. Berg D., Siefker C., Ruprecht-Dorfler P., and Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 56 (2001) 13-17
28. Walter U., Klein C., Hilker R., Benecke R., Pramstaller P., and Dressler D. Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 19 (2004) 1445-1449
29. Sommer U., Hummel T., Cormann K., Mueller A., Frasnelli J., Kropp J., et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 19 (2004) 1196-1202
30. Ponsen M., Stoffers D., Booij J., Van Eck-Smit B., Wolters E., and Berendse H. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 56 (2004) 173-181
31. 18F-dopa PET study. Ann Neurol 41 (1997) 222-229
32. Stiasny-Kolster K., Doerr Y., Moller J., Hoffken H., Behr T., Oertel W., et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha- synucleinopathy demonstrated by dopamine transporter FP-CITSPECT. Brain 128 (2005) 126-137
33. Brooks D. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol 53 (2003) S110-S119
34. 18F]dopa PET. J Neurol Neurosurg Psychiatry 64 (1998) 314-319
35. Ravina B., Eidelberg D., Ahlskog J., Albin R., Brooks D., Carbon M., et al. The role of radiotracer imaging in Parkinson's disease. Neurology 64 (2005) 208-215
36. Rascol O., Olanow W., Brooks D., Koch G., Truffinet P., and Bejuit R. A 2-year, multicenter, placebo-controlled, double-blind, parallel-group study of the effect of riluzole on Parkinson's disease progression. Mov Disord 17 Suppl (2002) P80
37. Whone A., Watts R., Stoessl J., Davis M., David M., Reske S., et al. Slower progression of PD with ropinirol versus L-dopa: the REAL- PET study. Ann Neurol 54 (2003) 93-101
38. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of Pramipexole vs levodopa Parkinson disease progression. J Am Med Assoc 287 (2002) 1653-1661
39. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 (2004) 2498-2508
40. Bohnen N., Minoshima S., Giordani B., Frey K., and Kuhl D. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 52 (1999) 541-546
41. 18FDG PET study. Brain 123 (2000) 340-352
42. Feigin A., Fukuda M., Dhawan V., Przedborski S., Jackson-Lewis V., Mentis M., et al. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 57 (2001) 2083-2088
43. Klunk W., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004) 306-319
44. Edison P., Rowe C., Rinne J., Ahmed I., Villemagne V., Ng S., et al. Amyloid load in Lewy body dementia (LBD), Parkinson's disease dementia (PDD) and Parkinson's disease (PD) measured with C-11- PIB PET. Neurology 68 (2007) A98
45. Walker Z., Costa D., Walker R., Shaw K., Gacinovic S., Stevens T., et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73 (2002) 134-140
46. Walker Z., Costa D., Walker R., Lee L., Livingston G., Jaros E., et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 62 (2004) 1568-1572
47. 18F]fluoro-L-dopa PET study. Brain 125 (2002) 1358-1365
48. 18F]fluorodopa positron emission tomographic study. Arch Neurol 57 (2000) 470-475
49. Schrag A., Good C., Miszkiel K., Morris H., Mathias C., Lees A., et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 54 (2000) 697-702
50. Nicoletti G., Fera F., Condino F., Auteri W., Gallo O., Pugliese P., et al. MR imaging of middle cerebellar peduncle width: differentiation of multiple system atrophy from Parkinson disease. Radiology 239 (2006) 825-830
51. Eidelberg D., Takikawa S., Moeller J., Dhawan V., Redington K., Chaly T., et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 33 (1993) 518-527
52. Druschky A., Hilz M., Platsch G., Radespiel-Troger M., Druschky K., Kuwert T., et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBGSPECT. J Neurol Sci 175 (2000) 3-12
53. 123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 53 (1999) 1020-1025
54. Nagayama H., Hamamoto M., Ueda M., Nagashima J., and Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 76 (2005) 249-251
55. Foster N., Gilman S., Berent S., Morin E., Brown M., and Koeppe R. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 24 (1988) 399-406